Richard Carvajal on Immunotherapy Dosing


Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.

Richard Carvajal, MD, from Columbia University Medical Center discusses deciding on dosing limits for immunotherapy treatments.

The proper dosing for immunotherapy efficacy is unclear. For chemotherapy, the patients can often be pushed to toxicity. However, with immunotherapies and targeted therapies, there are responses seen after 1 or 2 doses. There are also durable responses in some patients if treatment is stopped.

Related Videos
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
© 2023 MJH Life Sciences

All rights reserved.